Pott‐Junior 2021.

Study characteristics
Methods	Trial design: open‐label RCT with 4 parallel arms, the 3 intervention arms were pooled for this review Type of publication: journal publication Setting: inpatient Recruitment dates: July to December 2020 Country: Brazil Language: English Number of centres: 1 Study purpose (treatment, prevention): treatment Trial registration number: NCT04431466 Date of registration: 16 June 2020
Participants	Number of participants (randomized/analyzed): 32/31 Age (mean): overall 49 (SD 14.6) years Males, n: overall 17 (45%) Severity of condition according to study definition: hospitalized, mild clinical symptoms Severity of condition according to WHO scale: unclear; available information: minimum category 4, 20% in category 5 Co‐morbidities: NR Virus detection performed at baseline (test‐positive at baseline): RT‐PCR (100%) Inclusion criteria: diagnosis of infection by SARS‐CoV‐2 by symptoms of acute respiratory tract infection (sudden onset of ≥ 1 of the following: cough, fever, shortness of breath) and biomolecular diagnosis of SARS‐CoV‐2 infection or any acute respiratory disease AND biomolecular diagnosis of SARS‐CoV‐2 infection or severe acute respiratory infection (fever and ≥ 1 sign/symptom of respiratory disease, e.g. cough, fever, shortness of breath); need of hospitalization; biomolecular diagnosis of SARS‐CoV‐2 infection; Eastern Cooperative Oncology Group Performance Status score 0 to 1; National Early Warning Score 0–4; ability to understand and consent to participate in this clinical trial, manifested by signing the informed consent form. Exclusion criteria: inability to ingest study drug orally through spontaneous ingestion or use of enteral tubes; risk to participant in the trial judged by physician, based on patient history, clinical observation, laboratory test findings, ECG examination; known hypersensitivity to the components of the drugs used during the study; women in pregnancy or breastfeeding; bodyweight < 15 kg; estimated glomerular filtration rate < 30 mL/minute; AST or ALT > 5 times the upper limit of normality; refusal to participate or to sign the informed consent form
Interventions	Details of intervention Type and dose: ivermectin 0.1 mg/kg, 0.2 mg/kg, and 0.4 mg/kg cumulative over 72 hours, unclear frequency scheme (pooled) Route of administration: oral Treatment details of control group No treatment except standard of care Concomitant therapy: standard of care including thromboprophylaxis, steroids, antibiotics administered in both study arms, but unbalanced between groups Duration of follow‐up: 28 days Treatment cross‐overs: none
Outcomes	Primary study outcome Time to RT‐PCR negativity Relevant review outcomes reported Viral clearance (RT‐PCR) at 7 days Adverse events within 28 days ICU admission within 28 days Additional study outcomes reported Viral load variation clearance in nasopharyngeal swab at 7 days Time to undetectable viral load in nasopharyngeal swab at 7 days Change in cycle threshold values (RT‐PCR) within 7 days
Notes	Date of publication: 9 March 2021 Sponsor/funding: Federal University of Sao Carlos, Brazil Correspondence with the author team: author request sent (details of intervention, especially deviations between protocol and publication); no response received from the author Information on ethics votum: name of responsible ethics committee, reference number of proposal, and votum reported